X0M Stock Overview
Operates as a biotech royalty aggregator in the United States and the Asia Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
XOMA Royalty Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$22.60 |
| 52 Week High | US$24.20 |
| 52 Week Low | US$20.00 |
| Beta | 0.92 |
| 11 Month Change | 0.89% |
| 3 Month Change | -3.42% |
| 1 Year Change | 0% |
| 33 Year Change | 0.89% |
| 5 Year Change | n/a |
| Change since IPO | 12.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| X0M | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.3% | 2.8% |
| 1Y | 0% | -15.5% | 8.6% |
Return vs Industry: X0M exceeded the German Biotechs industry which returned -16.4% over the past year.
Return vs Market: X0M underperformed the German Market which returned 5.8% over the past year.
Price Volatility
| X0M volatility | |
|---|---|
| X0M Average Weekly Movement | 2.2% |
| Biotechs Industry Average Movement | 6.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: X0M has not had significant price volatility in the past 3 months.
Volatility Over Time: X0M's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 13 | Owen Hughes | xoma.com |
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.
XOMA Royalty Corporation Fundamentals Summary
| X0M fundamental statistics | |
|---|---|
| Market cap | €300.53m |
| Earnings (TTM) | -€22.49m |
| Revenue (TTM) | €13.65m |
22.9x
P/S Ratio-13.9x
P/E RatioIs X0M overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| X0M income statement (TTM) | |
|---|---|
| Revenue | US$15.24m |
| Cost of Revenue | US$1.24m |
| Gross Profit | US$14.00m |
| Other Expenses | US$39.10m |
| Earnings | -US$25.10m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.14 |
| Gross Margin | 91.84% |
| Net Profit Margin | -164.72% |
| Debt/Equity Ratio | 120.8% |
How did X0M perform over the long term?
See historical performance and comparison